Narrative review of Alzheimer's mechanisms, biomarkers and therapies from a geroscience view
This narrative review applies the eight hallmarks of neurodegenerative diseases as an analytical framework to Alzheimer's disease mechanisms, blood-based biomarkers and therapeutic prospects; the hallmarks are overlapping categories, not independent primary causes. [1]
Automatic summary · not editorially reviewed
The key findings
The review applies the eight hallmarks of neurodegenerative diseases as an analytical framework and notes they are overlapping categories, not independent primary causes. [1]
Anti-amyloid-β monoclonal antibodies substantially reduce amyloid burden and modestly slow clinical decline in early symptomatic Alzheimer's disease. [1]
Plasma phosphorylated tau 217 may improve biological detection, but clinical value depends on assay performance, intended use and patient context. [1]
The source at a glance
- Study type / format
- Narrative review (abstract only)
- Population / context
- People with Alzheimer's disease and the broader field of Alzheimer's research, as discussed in a narrative review
- Summary based on
- Study abstract
- Original publication
- September 2, 2026
Framework for Alzheimer's mechanisms and hallmarks
The review describes Alzheimer's disease as the leading cause of dementia and a heterogeneous neurodegenerative disorder marked by amyloid-β and tau pathology, impaired protein homeostasis, neurovascular dysfunction, maladaptive glial and immune responses, and synaptic dysfunction. Human genetic evidence supports an upstream role for amyloid-β. The authors apply the eight hallmarks of neurodegenerative diseases as an analytical framework and stress that these hallmarks overlap rather than acting as independent primary causes.
Supporting source [1]
Anti-amyloid antibodies and plasma p-tau 217
Anti-amyloid-β monoclonal antibodies substantially reduce amyloid burden and modestly slow clinical decline in early symptomatic Alzheimer's disease. Continued decline despite plaque removal is described as consistent with ongoing downstream tau pathology, glial responses and neuronal injury. Blood-based biomarkers, particularly plasma phosphorylated tau 217, may improve biological detection, but their clinical value depends on assay performance, intended use and patient context.
Supporting source [1]
Gut-brain modifiers and open therapeutic questions
Gut dysbiosis and gut-brain communication are treated separately as candidate systemic modifiers because causal evidence in humans remains insufficient. The review states that the therapeutic relevance of the hallmarks depends on disease stage and pathway activity. It calls for future studies to establish which preventive strategies and biomarker-guided, stage-matched combination therapies improve clinically meaningful outcomes and to identify the patients most likely to benefit.
Supporting source [1]
How to interpret this
This is a narrative review; the supplied abstract does not report a systematic search, study selection, sample sizes or effect estimates. Statements about biomarkers and therapies are framed as prospects, and the gut-brain discussion is explicitly noted as lacking sufficient causal evidence in humans. Only the abstract was reviewed; the full text was not reviewed.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Piotr Paweł Chmielewski · doi.org · September 2, 2026